Over the next year, countries that are home to 40% of the world’s population are set to get access to Ozempic and Wegovy generics that could cost as little as $15 a month.
Tahir Amin is a Staff Reporter at various esteemed publications. He covers a range of themes including finance, investment, telecommunications, and transportation, with a focus on topics such as 5G technology, telecommunications infrastructure, and international finance. Tahir's work has been featured in Space Today, BioSpace, STAT News, Business Recorder, RamaOnHealthcare, businessline, and TechJuice.












